GSB-106

What is GSB-106?

GSB-106 is a synthetic dimeric dipeptide designed to reproduce the bioactive conformation of the fourth beta-turn loop of brain-derived neurotrophic factor (BDNF) — the region of the full-length neurotrophin thought to drive binding to the TrkB receptor. It was developed at the V.V. Zakusov Research Institute of Pharmacology (part of the Russian Academy of Medical Sciences) in Moscow by the T.A. Gudasheva and S.B. Seredenin group, as the BDNF-mimetic counterpart to their NGF-mimetic GK-2. The stated design goal was a low-molecular-weight, metabolically stable molecule that could reproduce TrkB-mediated neurotrophic signaling in a form small enough to be orally active — something full-length BDNF, a 27 kDa protein, cannot be. GSB-106 has been reported in Russian peer-reviewed literature to produce antidepressant-like, anxiolytic, and neuroprotective effects in standard rodent models. It has not, to our knowledge, been tested in a published human clinical trial.

What GSB-106 Is Investigated For

GSB-106 is a mechanistically interesting molecule: a dimeric dipeptide designed to mimic the TrkB-binding loop of BDNF and to reproduce neurotrophin signaling in a drug-like, orally bioavailable format. The strongest support comes from preclinical rodent studies out of the Gudasheva and Seredenin group at the Zakusov Institute, which report antidepressant-like activity in the forced-swim and tail-suspension tests, anxiolytic effects in open-field and elevated-plus-maze assays, and neuroprotection in models of cerebral ischemia, Alzheimer's-type pathology, and Parkinson's-type lesions. The honest caveats are substantial and should be stated directly: almost all of the published efficacy data comes from a single research program, independent Western replication is limited, and — most importantly — no completed human randomized controlled trial of GSB-106 for depression, anxiety, stroke, or any other indication appears in the indexed clinical trial literature. Rodent behavioral despair assays are known to translate imperfectly to human depression. GSB-106 should be understood as a preclinical BDNF-mimetic drug candidate with a coherent rationale, not as a validated human therapy. It is also not the same thing as BDNF itself, and it is not interchangeable with BDNF-upregulating interventions like exercise, SSRIs, or ketamine, each of which works through different mechanisms with a different evidence base in humans.

History & Discovery

GSB-106 comes out of a long-running Russian medicinal-chemistry program at the V.V. Zakusov Research Institute of Pharmacology in Moscow, part of the Russian Academy of Medical Sciences. The program was led by Tatiana A. Gudasheva, with Sergey B. Seredenin as institute director and co-investigator, and it began from a deliberate design question: the neurotrophins — NGF, BDNF, NT-3, NT-4 — are among the most biologically interesting molecules in neuroscience, but they are large, unstable proteins that do not cross the blood-brain barrier after peripheral administration and are impractical as systemic drugs. Could the bioactive core of a neurotrophin be reproduced in a small molecule that kept the receptor-activating pharmacology but discarded the pharmaceutically inconvenient bulk? The group's approach was to focus on the individual beta-turn loops of each neurotrophin — the loops that published crystallographic and mutagenesis work had implicated in receptor binding — and to build small, symmetric dimeric dipeptides shaped to reproduce those loops in isolation. Dimerization was deliberate: the native neurotrophins are homodimers that engage their Trk receptors as dimers, and the Gudasheva design attempts to recapitulate that geometry at a much smaller scale. GK-2 was the first widely discussed compound from the program — a dimeric dipeptide mimetic of loop 4 of NGF, targeting TrkA, with reported neuroprotective activity in preclinical stroke and neurodegeneration models. GSB-106 is the BDNF counterpart: the loop 4 mimetic of BDNF, targeting TrkB. Its chemical structure — a bis-(N-monosuccinyl-L-seryl-L-methionine) hexamethylenediamide — reflects the same design grammar as GK-2 with a different amino-acid pair and a BDNF-derived receptor target. Published preclinical work on GSB-106 spans antidepressant-like activity in forced-swim and tail-suspension tests, anxiolytic effects in open-field and elevated-plus-maze assays, neuroprotection in focal cerebral ischemia, and activity in Alzheimer's-type and Parkinson's-type rodent models. The program has also reported mechanistic data showing TrkB activation and downstream Erk and Akt phosphorylation in cultured neurons. Most of this work has been published in Russian pharmacology and neuroscience journals, often in English-language translations indexed on PubMed, but the bulk of the efficacy record comes from the Gudasheva and Seredenin group rather than from independent Western laboratories. Public information about advancement into formal human clinical trials is limited; as of this writing, no completed randomized controlled trial of GSB-106 for any indication has been indexed in the major clinical trial registries we can verify.

How It Works

GSB-106 is a tiny synthetic molecule shaped to copy the part of BDNF — a natural brain growth factor — that latches onto the TrkB receptor on neurons. By engaging TrkB, it is designed to switch on some of the same growth and survival signals that BDNF normally turns on, without requiring the full-size BDNF protein.

GSB-106 is a bis-(N-monosuccinyl-L-seryl-L-methionine) hexamethylenediamide — a symmetric dimeric dipeptide built by linking two Ser-Met units through a hexamethylenediamine spacer attached via succinyl groups. The design is based on the reported bioactive conformation of the fourth beta-turn loop of BDNF, which contacts the TrkB receptor in the native neurotrophin. In preclinical studies from the Gudasheva and Seredenin group, GSB-106 is reported to activate TrkB and its canonical downstream signaling cascades — PI3K/Akt (survival), MAPK/ERK (plasticity and growth), and PLC-gamma — at sub-micromolar concentrations in cultured neurons, while producing antidepressant-like behavioral effects in rodents after oral dosing. Reported effects include restoration of hippocampal BDNF-related signaling after stress, neuroprotection against glutamate excitotoxicity in vitro, reduction of beta-amyloid-induced neuronal damage in Alzheimer's-type models, and functional recovery in ischemic stroke and MPTP-Parkinsonian rodent models. Whether the downstream signaling reproduces the full repertoire of native BDNF-TrkB signaling — including the specific receptor trafficking and sustained signaling patterns that distinguish endogenous neurotrophin responses from synthetic ligand engagement — is not fully established.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about GSB-106:

• 01Any completed human randomized controlled trial — no published Phase II or III study has tested GSB-106 in humans with depression, anxiety, stroke, Alzheimer's, or any other indication, and human efficacy therefore remains unproven.
• 02Human pharmacokinetics — oral bioavailability, plasma and CNS exposure, half-life, and metabolism in humans have not been characterized in any peer-reviewed publication we can verify.
• 03Independent preclinical replication — the efficacy record for GSB-106 comes largely from the Gudasheva and Seredenin group at the Zakusov Institute; independent reproduction of the antidepressant-like, anxiolytic, and neuroprotective findings by unaffiliated Western laboratories is limited.
• 04Chronic TrkB-mimetic safety — sustained TrkB activation has theoretical implications for cell proliferation and for neurotrophin receptor desensitization that have not been studied in long-duration animal studies at doses relevant to proposed human exposure.
• 05Comparative efficacy vs. established antidepressants and vs. other BDNF-upregulating interventions — GSB-106 has not been compared head-to-head with SSRIs, ketamine, exercise, or other BDNF-modulating approaches in humans, so relative efficacy and relative safety are unknown.
• 06Signaling fidelity vs. native BDNF — whether a small-molecule loop mimetic reproduces the full temporal and spatial pattern of native BDNF-TrkB signaling in vivo, or only a subset, has not been resolved and has implications for which BDNF-mediated effects should and should not be expected.
• 07Real-world product quality — research-chemical-channel GSB-106 lacks the identity, purity, and chain-of-custody verification that would let even informed users know what they are taking.

Forms & Administration

GSB-106 is reported in the preclinical literature to be active after oral administration in rodents at low-milligram-per-kilogram doses, which is unusual for a peptide and is a core design feature emphasized by the Gudasheva group. There is no established human formulation, no approved dosage form, and no pharmaceutical-grade product. Any research-chemical-channel GSB-106 should be treated as a research compound of unverified identity and purity.

Common Questions

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.